Abbott announced in early April that its TriClip transcatheter tricuspid valve repair system won CE Mark approval in Europe.
Abbott designed TriClip for people with a leaky tricuspid valve, otherwise known as tricuspid regurgitation (TR). The company touts it as the first minimally invasive, clip-based tricuspid valve repair device in the world to be made commercially available.
When untreated, TR can lead to atrial fibrillation, heart failure and death, and it typically occurs in older patients with multiple co-morbidities, making open-heart surgery a high-risk procedure. The TriClip repairs the tricuspid valve without the need for open-heart surgery.